• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Petros Pharmaceuticals, Inc. - Common Stock (NQ: PTPI )

    0.3509 +0.0401 (+12.90%)
    Streaming Delayed Price Updated: 4:00 PM EST, Dec 27, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Petros Pharmaceuticals, Inc. - Common Stock

    < Previous 1 2 Next >
    Petros Pharmaceuticals Featured in “New Era of Healthcare, AI, Data and Consumer Empowerment”
    Via ACCESSWIRE
    Proprietary Technology Addressing the Rx-to-OTC Switch Self-Care Market Valued at over $38 Billion annually
    Via ACCESSWIRE
    Petros Pharmaceuticals Executes Successful Initial Test for App Comprehension as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)
    Via ACCESSWIRE
    Petros Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
    Via ACCESSWIRE
    Petros Pharmaceuticals' Pivotal Statistically Significant Self Selection Study Shows Stronger Results with Proprietary Technology Application as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)
    Via ACCESSWIRE
    Petros Pharmaceuticals’ STENDRA(R) (avanafil) Pivotal Consumer Self-Selection Study for Over-the-Counter Access Demonstrates Statistical Significance
    Via ACCESSWIRE
    Petros Pharmaceuticals Activates Advisory Committee to Help Guide Rx-to-OTC Switch for STENDRA
    Via ACCESSWIRE
    Petros Pharmaceuticals Receives Positive Response from FDA Following Recent Demonstration of Technology Component in Pursuit of OTC Status for STENDRA(R) (avanafil)
    Via ACCESSWIRE
    Petros Pharmaceuticals Enters into AI Licensing Agreement with Leading Multi-Billion-Dollar Software Provider
    Via ACCESSWIRE
    Petros Pharmaceuticals Successfully Completes AI-Integrated Formative Human Factors Study Demonstrating Positive Interaction with Web App Designed for STENDRA(R) (avanafil) OTC Switch
    Via ACCESSWIRE
    Lemonaid Health Now Offers Prescription ED Medication STENDRAⓇ Through Collaboration with Petros Pharmaceuticals
    Lemonaid Health will offer customers more affordable access to fast-acting branded ED medication that works as quickly as 15 minutes prior to sexual activity 
    From 23andMe, Inc.
    Via GlobeNewswire
    Petros Pharmaceuticals Launches U.S. Distribution of Prescription ED Medication STENDRA Through Recently Announced Collaboration With Lemonaid Health, a Subsidiary of 23andMe
    Via ACCESSWIRE
    Petros Pharmaceuticals Expands Online Distribution for Prescription STENDRA(R) (avanafil) Through New Agreement with Lemonaid Health
    Via ACCESSWIRE
    Petros Pharmaceuticals Announces Two Upcoming FDA Meetings to Review Progress and Path Forward for STENDRA(R) (avanafil) Rx-to-OTC Switch
    Via ACCESSWIRE
    Petros Pharmaceuticals Partners with Blockbuster Cholesterol Drug(1) Crestor’s (rosuvastatin) OTC Switch Technology Provider
    Via ACCESSWIRE
    Petros Pharmaceuticals Partners with Blockbuster Cholesterol Drug(1) Crestor's (rosuvastatin) OTC Switch Technology Provider
    Via ACCESSWIRE
    Petros Pharmaceuticals Reports Positive Results in an Initial Cohort Two-Arm Self-Selection (Phase 2-Equivalent) Study for STENDRA(R) (avanafil) as it Pursues OTC Status
    Via ACCESSWIRE
    Petros Pharmaceuticals Successfully Launches AI Tool In Collaboration with Multi-Billion-Dollar Software Provider
    Via ACCESSWIRE
    BestGrowthStocks.Com Issues Comprehensive Analysis of Petros Pharmaceuticals Inc
    NEW YORK, NY / NewsDirect / March 11th, 2024 / Best Growth Stocks, a leading independent equity research and corporate access firm focused on finding and reporting on the best growth stocks utilizing... 
    Via TheNewswire.com
    Exposures Product Safety
    Petros Pharmaceuticals Demonstrates Positive Results Following Successful Completion of Initial Cohort of Phase 2 Equivalent Self-Selection Study for STENDRA (avanafil) Rx-to-OTC Switch
    Via ACCESSWIRE
    Petros Pharmaceuticals Successfully Completes Important Study in Effort to Make STENDRA(R) (avanafil) the First Erectile Dysfunction Medication to Achieve OTC Status
    Via ACCESSWIRE
    Following Encouraging FDA Feedback Petros Pharmaceuticals Initiates Self-Selection (Phase 2-Equivalent) Study for STENDRA
    Via ACCESSWIRE
    Petros Pharmaceuticals Announces Positive Outcomes in Label Comprehension Study for Potential OTC STENDRA Label
    Via ACCESSWIRE
    Petros Pharmaceuticals Provides Letter to Shareholders
    Via ACCESSWIRE
    Petros Pharmaceuticals Petros Pharmaceuticals Developing Artificial Intelligence Technology for Phase 2 Equivalent Study for STENDRA(R)
    Via ACCESSWIRE
    Petros Pharmaceuticals to Present at the LD Micro Main Event XVI
    Via ACCESSWIRE
    Petros Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
    Via ACCESSWIRE
    Petros Pharmaceuticals Announces Capital Raise of $15 Million
    Via ACCESSWIRE
    Petros Pharmaceuticals Announces Reverse Stock Split
    Via ACCESSWIRE
    Petros Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Update
    Via ACCESSWIRE
    < Previous 1 2 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.